COL4A1 and hepatocellular carcinoma: Results showed that both Defactinib and Saracatinib could significantly inhibit the growth of HCC cells with high expression of COL4A1 (SK-Hep1, Hep3B, and SMMC7721) (Fig. 6a), while they had little effect on inhibiting the growth of HCC cells with low expression of COL4A1 (PLC/PRF/5, HepG2, and Huh7) (Fig. 6b).